ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

QLC1401

A development code. Also written as “QLS1304 tablet+Fulvestrant or QLC1401” and “QLS1304 tablet+Fulvestrant,AI or QLC1401+CDK4/6i”.

Its studies are mostly in Breast Neoplasms, led by Qilu Pharmaceutical.

Furthest: phase 2, since Sep 7, 20252 company-led studies, 2 open or runningNext primary completion: Feb 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Qilu Pharmaceutical22 open or runningphase 2since Sep 7, 2025Sep 7, 2025Feb 2027phase 2 · NCT07173556

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 7, 2025First study: phase 2 study in Advanced Breast CancerFirst studyNCT07173556 · 96 planned
  2. Nov 14, 2025Phase 2 study in Advanced ER+/HER2- Breast CancerNCT07235176 · 300 planned · China

Ahead

  1. Feb 2027Primary completion: phase 2 study in Advanced Breast CancerNCT07173556
  2. Nov 2, 2028Primary completion: phase 2 study in Advanced ER+/HER2- Breast CancerNCT07235176

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07235176Advanced ER+/HER2- Breast Cancer · China2RecruitingNov 2, 2028300
NCT07173556Advanced Breast Cancer2Not yet recruitingFeb 202796

How it is read

Names in the registry

  • “QLC1401”, 2 entries
  • “QLS1304 tablet+Fulvestrant or QLC1401”, 1 entry
  • “QLS1304 tablet+Fulvestrant,AI or QLC1401+CDK4/6i”, 1 entry

Codes read as this program: QLC1401.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.